92 filings
Page 3 of 5
6-K
7a1 n53xbi
15 Aug 22
Current report (foreign)
6:05am
6-K
dqviu32czhk
26 Jul 22
Addex Completes $4.2 Million Equity Financing
4:06pm
6-K
cbtvj7p6
22 Jul 22
Current report (foreign)
6:05am
6-K
m2towf
21 Jul 22
Addex Completes Reduction in Nominal Value of Shares
6:05am
6-K
bxv8f0f6j 03
21 Jul 22
Addex Provides Corporate Update and Financial Guidance
6:05am
6-K
6yfufv5
17 Jun 22
Current report (foreign)
6:05am
6-K
gkqhokf 57pqepma
27 May 22
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
6:05am
6-K
azjhpymi90r mtgw6a
10 May 22
Addex Shareholders Approve All Resolutions at Annual General Meeting
6:05am
6-K
qcpobsax
5 May 22
Current report (foreign)
6:03am
6-K
67jq7z5r8x49k4r
13 Apr 22
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study
6:05am
6-K
elqfmuoa2y1c
6 Apr 22
Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders
6:05am
6-K
pma95vwp93wd0
31 Mar 22
Addex Convenes Annual General Meeting 2022
6:05am
6-K
34qkn
10 Mar 22
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update
6:05am
6-K
gyx9xrk1unws4scl
3 Feb 22
Addex Increases Issued Share Capital to Create Treasury Shares
6:05am
6-K
x4tfp
20 Dec 21
Current report (foreign)
12:00am
6-K
5to4kek0jy49
15 Dec 21
Addex Provides Year End Pipeline Development Update
9:38am
6-K
ya7jdsfn
15 Nov 21
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
6:05am
6-K
p73sp
4 Nov 21
Current report (foreign)
7:00am
6-K
2olz6x
29 Sep 21
Current report (foreign)
6:05am
6-K
p4foh6
22 Sep 21
Current report (foreign)
6:05am